Cargando…

Endometrial Stromal Sarcomas: A Revision of Their Potential as Targets for Immunotherapy

Endometrial stromal sarcomas are a subtype of uterine sarcomas that are characterized by recurrent chromosomal translocations, resulting in the expression of tumor-specific fusion proteins that contribute to their tumorigenicity. These characteristics make the translocation breakpoints promising tar...

Descripción completa

Detalles Bibliográficos
Autores principales: Tuyaerts, Sandra, Amant, Frédéric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6161160/
https://www.ncbi.nlm.nih.gov/pubmed/30149610
http://dx.doi.org/10.3390/vaccines6030056
_version_ 1783358929768546304
author Tuyaerts, Sandra
Amant, Frédéric
author_facet Tuyaerts, Sandra
Amant, Frédéric
author_sort Tuyaerts, Sandra
collection PubMed
description Endometrial stromal sarcomas are a subtype of uterine sarcomas that are characterized by recurrent chromosomal translocations, resulting in the expression of tumor-specific fusion proteins that contribute to their tumorigenicity. These characteristics make the translocation breakpoints promising targets for immunotherapeutic approaches. In this review, we first describe the current knowledge about the classification of endometrial stromal sarcomas, and their molecular and genetic characteristics. Next, we summarize the available data on the use of translocation breakpoints as immunotherapeutic targets. Finally, we propose a roadmap to evaluate the feasibility of immunologic targeting of the endometrial stromal sarcoma-specific translocations in patients with recurrent disease.
format Online
Article
Text
id pubmed-6161160
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-61611602018-10-01 Endometrial Stromal Sarcomas: A Revision of Their Potential as Targets for Immunotherapy Tuyaerts, Sandra Amant, Frédéric Vaccines (Basel) Review Endometrial stromal sarcomas are a subtype of uterine sarcomas that are characterized by recurrent chromosomal translocations, resulting in the expression of tumor-specific fusion proteins that contribute to their tumorigenicity. These characteristics make the translocation breakpoints promising targets for immunotherapeutic approaches. In this review, we first describe the current knowledge about the classification of endometrial stromal sarcomas, and their molecular and genetic characteristics. Next, we summarize the available data on the use of translocation breakpoints as immunotherapeutic targets. Finally, we propose a roadmap to evaluate the feasibility of immunologic targeting of the endometrial stromal sarcoma-specific translocations in patients with recurrent disease. MDPI 2018-08-25 /pmc/articles/PMC6161160/ /pubmed/30149610 http://dx.doi.org/10.3390/vaccines6030056 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Tuyaerts, Sandra
Amant, Frédéric
Endometrial Stromal Sarcomas: A Revision of Their Potential as Targets for Immunotherapy
title Endometrial Stromal Sarcomas: A Revision of Their Potential as Targets for Immunotherapy
title_full Endometrial Stromal Sarcomas: A Revision of Their Potential as Targets for Immunotherapy
title_fullStr Endometrial Stromal Sarcomas: A Revision of Their Potential as Targets for Immunotherapy
title_full_unstemmed Endometrial Stromal Sarcomas: A Revision of Their Potential as Targets for Immunotherapy
title_short Endometrial Stromal Sarcomas: A Revision of Their Potential as Targets for Immunotherapy
title_sort endometrial stromal sarcomas: a revision of their potential as targets for immunotherapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6161160/
https://www.ncbi.nlm.nih.gov/pubmed/30149610
http://dx.doi.org/10.3390/vaccines6030056
work_keys_str_mv AT tuyaertssandra endometrialstromalsarcomasarevisionoftheirpotentialastargetsforimmunotherapy
AT amantfrederic endometrialstromalsarcomasarevisionoftheirpotentialastargetsforimmunotherapy